https://www.uksh.de/Das+UKSH/Presse/Presseinformationen/2025/Personalisierte+The... https://tu-dresden.de/med/mf/die-fakultaet/newsuebersicht/personalisierte-therap ...
Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report) is expected to be issuing its quarterly earnings data after the market ...
Nuvation Bio Inc : * NUVATION BIO DÉCROCHE JUSQU'À 250 MILLIONS DE DOLLARS DE FINANCEMENTS NON DILUTIFS AUPRÈS DE SAGARD ...
Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for Rigel Pharmaceuticals ...
Rigel Pharmaceuticals has put up a strong performance in 2024 and should maintain momentum in 2025. Irrespective of how the ...
The drug is indicated for the treatment of adult patients with relapsed or refractory (R/R) mutated isocitrate dehydrogenase-1 (mIDH1) acute myeloid leukemia (AM R/R AML with a susceptible IDH1 ...
Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 ...
Fourth quarter 2024 total revenue of approximately $57.6 million, which includes TAVALISSE® net product sales of $31.0 million, REZLIDHIA® net product sales of $7.4 million and GAVRETO® net product ...
Recent research suggests that RNA splicing errors can generate unique TSAs, particularly in gliomas with mutations in the genes encoding isocitrate dehydrogenase (IDH). These mutations are known ...
CD74, cluster of differentiation 74; IDH, isocitrate dehydrogenase; MGMT, O6-methylguanine-DNA methyltransferase; HLA, human lymphocyte antigen; MIF, macrophage migration inhibitory factor; TCGA, The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback